| Primary |
| Acute Lymphocytic Leukaemia |
25.0% |
| B-cell Lymphoma |
25.0% |
| Non-hodgkin's Lymphoma |
25.0% |
| Leukaemia Plasmacytic |
18.8% |
| T-cell Lymphoma |
6.3% |
|
| Polyneuropathy |
25.0% |
| Bacterial Sepsis |
12.5% |
| Cellulitis |
12.5% |
| Ileus Paralytic |
12.5% |
| Renal Failure Acute |
12.5% |
| Superinfection |
12.5% |
| Wrong Drug Administered |
12.5% |
|
| Secondary |
| Non-hodgkin's Lymphoma |
11.6% |
| B-cell Lymphoma |
10.7% |
| Diffuse Large B-cell Lymphoma |
9.9% |
| Acute Lymphocytic Leukaemia |
9.5% |
| Hodgkin's Disease |
8.1% |
| Adult T-cell Lymphoma/leukaemia |
6.9% |
| Burkitt's Lymphoma |
6.6% |
| Lymphoma |
6.5% |
| Drug Use For Unknown Indication |
5.6% |
| Product Used For Unknown Indication |
4.9% |
| Prophylaxis |
4.7% |
| Rhabdomyosarcoma |
2.5% |
| Mantle Cell Lymphoma |
2.0% |
| Multiple Myeloma |
1.9% |
| Chronic Lymphocytic Leukaemia |
1.9% |
| Hypertension |
1.6% |
| Diffuse Large B-cell Lymphoma Stage Iv |
1.6% |
| Chronic Myeloid Leukaemia |
1.5% |
| Neoplasm Malignant |
1.0% |
| Chemotherapy |
0.9% |
|
| White Blood Cell Count Decreased |
15.3% |
| Pulmonary Toxicity |
7.6% |
| Interstitial Lung Disease |
6.5% |
| Ejection Fraction Decreased |
5.4% |
| Neutropenia |
5.4% |
| Pneumonia |
5.2% |
| Tremor |
5.2% |
| Hepatitis B |
4.6% |
| Polyneuropathy |
4.1% |
| Septic Shock |
4.1% |
| Thrombocytopenia |
4.1% |
| Neuropathy Peripheral |
3.8% |
| Progressive Multifocal Leukoencephalopathy |
3.8% |
| Renal Impairment |
3.8% |
| Sepsis |
3.8% |
| Traumatic Lung Injury |
3.8% |
| Multi-organ Failure |
3.5% |
| Febrile Neutropenia |
3.3% |
| Intracardiac Thrombus |
3.3% |
| Lung Adenocarcinoma Stage I |
3.3% |
|
| Concomitant |
| Non-hodgkin's Lymphoma |
13.5% |
| Neoplasm Malignant |
11.7% |
| Lymphoma |
10.0% |
| Drug Use For Unknown Indication |
8.7% |
| Product Used For Unknown Indication |
8.4% |
| Prophylaxis |
7.4% |
| Acute Lymphocytic Leukaemia |
6.2% |
| Burkitt's Lymphoma |
6.0% |
| B-cell Lymphoma |
4.8% |
| Diffuse Large B-cell Lymphoma |
4.4% |
| Chemotherapy |
3.8% |
| Stem Cell Transplant |
2.1% |
| Adult T-cell Lymphoma/leukaemia |
1.9% |
| T-cell Type Acute Leukaemia |
1.8% |
| Hypertension |
1.8% |
| Hodgkin's Disease |
1.7% |
| Chronic Myeloid Leukaemia |
1.5% |
| Multiple Myeloma |
1.5% |
| Acute Biphenotypic Leukaemia |
1.4% |
| Hiv Infection |
1.4% |
|
| Vomiting |
19.3% |
| White Blood Cell Count Decreased |
11.4% |
| Pleural Effusion |
6.7% |
| Somnolence |
6.3% |
| Sepsis |
5.9% |
| Renal Impairment |
5.1% |
| Pneumocystis Jiroveci Pneumonia |
4.7% |
| Thrombocytopenia |
3.9% |
| Gastric Antral Vascular Ectasia |
3.5% |
| Neutropenia |
3.5% |
| Progressive Multifocal Leukoencephalopathy |
3.5% |
| Death |
3.1% |
| Drug Ineffective |
3.1% |
| Malignant Neoplasm Progression |
3.1% |
| Treatment Related Secondary Malignancy |
3.1% |
| X-ray Abnormal |
3.1% |
| Hepatitis Fulminant |
2.8% |
| Interstitial Lung Disease |
2.8% |
| Pancreatitis Acute |
2.4% |
| Platelet Count Decreased |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
20.8% |
| Acute Lymphocytic Leukaemia |
16.7% |
| Prophylaxis |
15.7% |
| Lymphoma |
15.5% |
| B-cell Lymphoma |
5.4% |
| Hypertension |
4.8% |
| Product Used For Unknown Indication |
3.6% |
| Haematopoietic Neoplasm |
3.2% |
| Antibiotic Prophylaxis |
2.4% |
| Infection |
2.4% |
| Antifungal Treatment |
2.2% |
| Diffuse Large B-cell Lymphoma |
1.8% |
| Antifungal Prophylaxis |
1.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.6% |
| Constipation |
1.2% |
| T-cell Type Acute Leukaemia |
0.8% |
| Gastric Ulcer |
0.6% |
|
| Ileus Paralytic |
32.1% |
| Myalgia |
28.3% |
| Drug Interaction |
13.2% |
| Pyrexia |
9.4% |
| Chest Discomfort |
3.8% |
| Malaise |
3.8% |
| Neuropathy Peripheral |
3.8% |
| Hypokinesia |
1.9% |
| Monoplegia |
1.9% |
| Pain In Extremity |
1.9% |
|
